Cite
HARVARD Citation
Long, G. et al. (n.d.). 429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma. Journal for immunotherapy of cancer. p. A261. [Online].